NO300416B1 - 3,5-substituerte aminobenzoylguanidiner, deres anvendelse til fremstilling av medikament eller diagnostikum - Google Patents
3,5-substituerte aminobenzoylguanidiner, deres anvendelse til fremstilling av medikament eller diagnostikum Download PDFInfo
- Publication number
- NO300416B1 NO300416B1 NO934634A NO934634A NO300416B1 NO 300416 B1 NO300416 B1 NO 300416B1 NO 934634 A NO934634 A NO 934634A NO 934634 A NO934634 A NO 934634A NO 300416 B1 NO300416 B1 NO 300416B1
- Authority
- NO
- Norway
- Prior art keywords
- compound
- preparation
- hydrogen
- treatment
- substituents
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 22
- 229940079593 drug Drugs 0.000 title claims description 14
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- VUKXXOLBVCEOPX-UHFFFAOYSA-N 1-amino-1-benzoylguanidine Chemical class NC(=N)N(N)C(=O)C1=CC=CC=C1 VUKXXOLBVCEOPX-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 47
- 238000011282 treatment Methods 0.000 claims description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims description 28
- 239000001257 hydrogen Substances 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- -1 5-trifluoromethyl-3-N,N-dimethyl-aminobenzoylguanidine hydrochloride Chemical compound 0.000 claims description 12
- 229910052801 chlorine Inorganic materials 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- 150000002431 hydrogen Chemical class 0.000 claims description 11
- 238000011321 prophylaxis Methods 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 229910052794 bromium Inorganic materials 0.000 claims description 8
- 210000000056 organ Anatomy 0.000 claims description 8
- 230000000302 ischemic effect Effects 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 230000002093 peripheral effect Effects 0.000 claims description 5
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 230000035939 shock Effects 0.000 claims description 4
- LINCETFYJLYKAM-UHFFFAOYSA-N 4-amino-3,5-dibromo-n-(diaminomethylidene)benzamide;hydrochloride Chemical compound Cl.NC(=N)NC(=O)C1=CC(Br)=C(N)C(Br)=C1 LINCETFYJLYKAM-UHFFFAOYSA-N 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 206010023421 Kidney fibrosis Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 230000000879 anti-atherosclerotic effect Effects 0.000 claims description 3
- 206010003119 arrhythmia Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 230000003176 fibrotic effect Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- JGUNGKOJVLIGRX-UHFFFAOYSA-N 2-amino-3,5-dichloro-n-(diaminomethylidene)benzamide;hydrochloride Chemical compound Cl.NC(=N)NC(=O)C1=CC(Cl)=CC(Cl)=C1N JGUNGKOJVLIGRX-UHFFFAOYSA-N 0.000 claims description 2
- 230000006793 arrhythmia Effects 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 238000011477 surgical intervention Methods 0.000 claims description 2
- 210000004211 gastric acid Anatomy 0.000 claims 1
- 238000002844 melting Methods 0.000 description 26
- 230000008018 melting Effects 0.000 description 26
- 239000000126 substance Substances 0.000 description 26
- 238000007429 general method Methods 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 8
- 229960002576 amiloride Drugs 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000003288 anthiarrhythmic effect Effects 0.000 description 4
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- AJDQRQQNNLZLPM-UHFFFAOYSA-N n-(diaminomethylidene)benzamide Chemical class NC(N)=NC(=O)C1=CC=CC=C1 AJDQRQQNNLZLPM-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- QDERNBXNXJCIQK-UHFFFAOYSA-N ethylisopropylamiloride Chemical compound CCN(C(C)C)C1=NC(N)=C(C(=O)N=C(N)N)N=C1Cl QDERNBXNXJCIQK-UHFFFAOYSA-N 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- HJVAVGOPTDJYOJ-UHFFFAOYSA-N 2-amino-4,5-dimethoxybenzoic acid Chemical compound COC1=CC(N)=C(C(O)=O)C=C1OC HJVAVGOPTDJYOJ-UHFFFAOYSA-N 0.000 description 2
- WBTHOSZMTIPJLR-UHFFFAOYSA-N 3-amino-5-(trifluoromethyl)benzoic acid Chemical compound NC1=CC(C(O)=O)=CC(C(F)(F)F)=C1 WBTHOSZMTIPJLR-UHFFFAOYSA-N 0.000 description 2
- RXMUPNVSYKGKMY-UHFFFAOYSA-N 3-amino-6-chloro-n-(diaminomethylidene)-5-(dimethylamino)pyrazine-2-carboxamide Chemical compound CN(C)C1=NC(N)=C(C(=O)N=C(N)N)N=C1Cl RXMUPNVSYKGKMY-UHFFFAOYSA-N 0.000 description 2
- QJPIWSPEZDLWMG-UHFFFAOYSA-N 4-amino-3,5-dichloro-n-(diaminomethylidene)benzamide;dihydrochloride Chemical compound Cl.Cl.NC(=N)NC(=O)C1=CC(Cl)=C(N)C(Cl)=C1 QJPIWSPEZDLWMG-UHFFFAOYSA-N 0.000 description 2
- UHXYYTSWBYTDPD-UHFFFAOYSA-N 4-amino-3,5-dichlorobenzoic acid Chemical compound NC1=C(Cl)C=C(C(O)=O)C=C1Cl UHXYYTSWBYTDPD-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 208000007530 Essential hypertension Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000054 salidiuretic effect Effects 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IOHPVZBSOKLVMN-UHFFFAOYSA-N 2-(2-phenylethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 IOHPVZBSOKLVMN-UHFFFAOYSA-N 0.000 description 1
- WNAJXPYVTFYEST-UHFFFAOYSA-N 2-Amino-3-methylbenzoate Chemical compound CC1=CC=CC(C(O)=O)=C1N WNAJXPYVTFYEST-UHFFFAOYSA-N 0.000 description 1
- KTHTXLUIEAIGCD-UHFFFAOYSA-N 2-amino-3,5-dichlorobenzoic acid Chemical compound NC1=C(Cl)C=C(Cl)C=C1C(O)=O KTHTXLUIEAIGCD-UHFFFAOYSA-N 0.000 description 1
- NXFLLOULINNOTO-UHFFFAOYSA-N 2-amino-4,5-dibromo-n-(diaminomethylidene)benzamide;dihydrochloride Chemical compound Cl.Cl.NC(=N)NC(=O)C1=CC(Br)=C(Br)C=C1N NXFLLOULINNOTO-UHFFFAOYSA-N 0.000 description 1
- RJQGTUPMSDNELX-UHFFFAOYSA-N 2-amino-4,5-dibromobenzoic acid Chemical compound NC1=CC(Br)=C(Br)C=C1C(O)=O RJQGTUPMSDNELX-UHFFFAOYSA-N 0.000 description 1
- ZCGDZNHBRQEICC-UHFFFAOYSA-N 2-amino-n-(diaminomethylidene)-3-methylbenzamide;hydrochloride Chemical compound Cl.CC1=CC=CC(C(=O)NC(N)=N)=C1N ZCGDZNHBRQEICC-UHFFFAOYSA-N 0.000 description 1
- RFKAAUXZBXYEEW-UHFFFAOYSA-N 2-amino-n-(diaminomethylidene)-4,5-dimethoxybenzamide;dihydrochloride Chemical compound Cl.Cl.COC1=CC(N)=C(C(=O)NC(N)=N)C=C1OC RFKAAUXZBXYEEW-UHFFFAOYSA-N 0.000 description 1
- HFYNOMJCRJNIFL-UHFFFAOYSA-N 3,5-dibromo-4-(butylamino)-n-(diaminomethylidene)benzamide;dihydrochloride Chemical compound Cl.Cl.CCCCNC1=C(Br)C=C(C(=O)NC(N)=N)C=C1Br HFYNOMJCRJNIFL-UHFFFAOYSA-N 0.000 description 1
- MVDPTKNZWDDXLD-UHFFFAOYSA-N 3,5-dibromo-4-(butylamino)benzoic acid Chemical compound CCCCNC1=C(Br)C=C(C(O)=O)C=C1Br MVDPTKNZWDDXLD-UHFFFAOYSA-N 0.000 description 1
- SEKWWBAEVYIBCF-UHFFFAOYSA-N 3,5-dibromo-4-[(4-fluorophenyl)methylamino]benzoic acid Chemical compound BrC1=CC(C(=O)O)=CC(Br)=C1NCC1=CC=C(F)C=C1 SEKWWBAEVYIBCF-UHFFFAOYSA-N 0.000 description 1
- NSVPINHFVOMAKE-UHFFFAOYSA-N 3,5-dibromo-n-(diaminomethylidene)-4-[(4-fluorophenyl)methylamino]benzamide;hydrochloride Chemical compound Cl.BrC1=CC(C(=O)NC(=N)N)=CC(Br)=C1NCC1=CC=C(F)C=C1 NSVPINHFVOMAKE-UHFFFAOYSA-N 0.000 description 1
- BWPPEZJHELCMDU-UHFFFAOYSA-N 3,5-dichloro-4-(dimethylamino)benzoic acid Chemical compound CN(C)C1=C(Cl)C=C(C(O)=O)C=C1Cl BWPPEZJHELCMDU-UHFFFAOYSA-N 0.000 description 1
- RGILMRXHJGRKCX-UHFFFAOYSA-N 3,5-dichloro-n-(diaminomethylidene)-4-(dimethylamino)benzamide;hydrochloride Chemical compound Cl.CN(C)C1=C(Cl)C=C(C(=O)NC(N)=N)C=C1Cl RGILMRXHJGRKCX-UHFFFAOYSA-N 0.000 description 1
- WMYMUBYJLXSUKA-UHFFFAOYSA-N 3-(methylamino)-5-(trifluoromethyl)benzoic acid Chemical compound CNC1=CC(C(O)=O)=CC(C(F)(F)F)=C1 WMYMUBYJLXSUKA-UHFFFAOYSA-N 0.000 description 1
- TZSUDPDYOMUCRR-UHFFFAOYSA-N 3-amino-5-chloro-n-(diaminomethylidene)benzamide;dihydrochloride Chemical compound Cl.Cl.NC(=N)NC(=O)C1=CC(N)=CC(Cl)=C1 TZSUDPDYOMUCRR-UHFFFAOYSA-N 0.000 description 1
- ATFAXWNNFCBZNY-UHFFFAOYSA-N 3-amino-5-chlorobenzoic acid Chemical compound NC1=CC(Cl)=CC(C(O)=O)=C1 ATFAXWNNFCBZNY-UHFFFAOYSA-N 0.000 description 1
- HFFCHCQTNGGVGS-UHFFFAOYSA-N 3-amino-n-(diaminomethylidene)-5-(trifluoromethyl)benzamide;hydrochloride Chemical compound Cl.NC(=N)NC(=O)C1=CC(N)=CC(C(F)(F)F)=C1 HFFCHCQTNGGVGS-UHFFFAOYSA-N 0.000 description 1
- OUSDHMPCGYOLSO-UHFFFAOYSA-N 3-bromo-5-(dimethylamino)-4-methylbenzoic acid Chemical compound CN(C)C1=CC(C(O)=O)=CC(Br)=C1C OUSDHMPCGYOLSO-UHFFFAOYSA-N 0.000 description 1
- NWOMVQDBDBUANF-UHFFFAOYSA-N 3-bromo-5-methylbenzoic acid Chemical compound CC1=CC(Br)=CC(C(O)=O)=C1 NWOMVQDBDBUANF-UHFFFAOYSA-N 0.000 description 1
- IHBDCUDGVGIBOU-UHFFFAOYSA-N 3-bromo-n-(diaminomethylidene)-5-(dimethylamino)-4-methylbenzamide;hydrochloride Chemical compound Cl.CN(C)C1=CC(C(=O)NC(N)=N)=CC(Br)=C1C IHBDCUDGVGIBOU-UHFFFAOYSA-N 0.000 description 1
- HMELLIFKGCZNBA-UHFFFAOYSA-N 3-bromo-n-(diaminomethylidene)-5-methylbenzamide;hydrochloride Chemical compound Cl.CC1=CC(Br)=CC(C(=O)NC(N)=N)=C1 HMELLIFKGCZNBA-UHFFFAOYSA-N 0.000 description 1
- IIKKDSFPVDQZOD-UHFFFAOYSA-N 3-chloro-4-(dimethylamino)-5-methylbenzoic acid Chemical compound CN(C)C1=C(C)C=C(C(O)=O)C=C1Cl IIKKDSFPVDQZOD-UHFFFAOYSA-N 0.000 description 1
- PNFGHOIHUCAWFR-UHFFFAOYSA-N 3-chloro-5-(dimethylamino)-4-methoxybenzoic acid Chemical compound COC1=C(Cl)C=C(C(O)=O)C=C1N(C)C PNFGHOIHUCAWFR-UHFFFAOYSA-N 0.000 description 1
- AVAUTVOLQIVLCO-UHFFFAOYSA-N 3-chloro-5-(ethylamino)benzoic acid Chemical compound CCNC1=CC(Cl)=CC(C(O)=O)=C1 AVAUTVOLQIVLCO-UHFFFAOYSA-N 0.000 description 1
- PRYPHPLCXAHCIJ-UHFFFAOYSA-N 3-chloro-5-[(4-chlorophenyl)methylamino]-n-(diaminomethylidene)benzamide;dihydrochloride Chemical compound Cl.Cl.NC(=N)NC(=O)C1=CC(Cl)=CC(NCC=2C=CC(Cl)=CC=2)=C1 PRYPHPLCXAHCIJ-UHFFFAOYSA-N 0.000 description 1
- IVWPDWWODSXUQI-UHFFFAOYSA-N 3-chloro-n-(diaminomethylidene)-4-(dimethylamino)-5-methylbenzamide;dihydrochloride Chemical compound Cl.Cl.CN(C)C1=C(C)C=C(C(=O)NC(N)=N)C=C1Cl IVWPDWWODSXUQI-UHFFFAOYSA-N 0.000 description 1
- RQYJKRVZALXPKD-UHFFFAOYSA-N 3-chloro-n-(diaminomethylidene)-5-(dimethylamino)-4-methoxybenzamide;dihydrochloride Chemical compound Cl.Cl.COC1=C(Cl)C=C(C(=O)NC(N)=N)C=C1N(C)C RQYJKRVZALXPKD-UHFFFAOYSA-N 0.000 description 1
- UIPYVDSBIZQETO-UHFFFAOYSA-N 3-chloro-n-(diaminomethylidene)-5-(ethylamino)benzamide;dihydrochloride Chemical compound Cl.Cl.CCNC1=CC(Cl)=CC(C(=O)NC(N)=N)=C1 UIPYVDSBIZQETO-UHFFFAOYSA-N 0.000 description 1
- VWYQFZKTKAMCLU-UHFFFAOYSA-N 4-amino-3,5-dibromobenzoic acid Chemical compound NC1=C(Br)C=C(C(O)=O)C=C1Br VWYQFZKTKAMCLU-UHFFFAOYSA-N 0.000 description 1
- NZEOOPXCKUWJDQ-UHFFFAOYSA-N 4-amino-3,5-dimethylbenzoic acid Chemical compound CC1=CC(C(O)=O)=CC(C)=C1N NZEOOPXCKUWJDQ-UHFFFAOYSA-N 0.000 description 1
- QDVXQZIEVDLRRT-UHFFFAOYSA-N 4-amino-3-chloro-5-methylbenzoic acid Chemical compound CC1=CC(C(O)=O)=CC(Cl)=C1N QDVXQZIEVDLRRT-UHFFFAOYSA-N 0.000 description 1
- PAJLDAMOGVEEPD-UHFFFAOYSA-N 4-amino-3-chloro-n-(diaminomethylidene)-5-methylbenzamide;dihydrochloride Chemical compound Cl.Cl.CC1=CC(C(=O)NC(N)=N)=CC(Cl)=C1N PAJLDAMOGVEEPD-UHFFFAOYSA-N 0.000 description 1
- YAGLUNMFTFHFRA-UHFFFAOYSA-N 4-amino-n-(diaminomethylidene)-3,5-dimethylbenzamide;dihydrochloride Chemical compound Cl.Cl.CC1=CC(C(=O)NC(N)=N)=CC(C)=C1N YAGLUNMFTFHFRA-UHFFFAOYSA-N 0.000 description 1
- TYTDINDFLWOUBN-UHFFFAOYSA-N 5-chloro-2-(dimethylamino)benzoic acid Chemical compound CN(C)C1=CC=C(Cl)C=C1C(O)=O TYTDINDFLWOUBN-UHFFFAOYSA-N 0.000 description 1
- WOHHTJDKKUWELH-UHFFFAOYSA-N 5-chloro-n-(diaminomethylidene)-2-(dimethylamino)benzamide;hydrochloride Chemical compound Cl.CN(C)C1=CC=C(Cl)C=C1C(=O)NC(N)=N WOHHTJDKKUWELH-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- RMQDWYXHAXUPMH-UHFFFAOYSA-N Cl.CNNC(=N)N(NC)C(=O)C1=CC=CC(C(F)(F)F)=C1 Chemical compound Cl.CNNC(=N)N(NC)C(=O)C1=CC=CC(C(F)(F)F)=C1 RMQDWYXHAXUPMH-UHFFFAOYSA-N 0.000 description 1
- OEZYAKOQKKTLNF-UHFFFAOYSA-N Cl.Cl.CNNC(N(NC)C(C1=CC=CC(=C1)Cl)=O)=N Chemical compound Cl.Cl.CNNC(N(NC)C(C1=CC=CC(=C1)Cl)=O)=N OEZYAKOQKKTLNF-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 244000165918 Eucalyptus papuana Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229940122767 Potassium sparing diuretic Drugs 0.000 description 1
- 102000052126 Sodium-Hydrogen Exchangers Human genes 0.000 description 1
- 108091006672 Sodium–hydrogen antiporter Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- FPQVGDGSRVMNMR-JCTPKUEWSA-N [[(z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.CCOC(=O)C(\C#N)=N/OC(N(C)C)=[N+](C)C FPQVGDGSRVMNMR-JCTPKUEWSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- 230000001269 cardiogenic effect Effects 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000002178 gastroprotective effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 150000007928 imidazolide derivatives Chemical class 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- SZHUKIVIYRQCOH-UHFFFAOYSA-N n-(diaminomethylidene)-3-(methylamino)-5-(trifluoromethyl)benzamide;dihydrochloride Chemical compound Cl.Cl.CNC1=CC(C(=O)NC(N)=N)=CC(C(F)(F)F)=C1 SZHUKIVIYRQCOH-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012434 nucleophilic reagent Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000003286 potassium sparing diuretic agent Substances 0.000 description 1
- 229940097241 potassium-sparing diuretic Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 201000004240 prostatic hypertrophy Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000894 saliuretic effect Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4242554 | 1992-12-16 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO934634D0 NO934634D0 (no) | 1993-12-15 |
| NO934634L NO934634L (no) | 1994-06-17 |
| NO300416B1 true NO300416B1 (no) | 1997-05-26 |
Family
ID=6475499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO934634A NO300416B1 (no) | 1992-12-16 | 1993-12-15 | 3,5-substituerte aminobenzoylguanidiner, deres anvendelse til fremstilling av medikament eller diagnostikum |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5516805A (ja) |
| EP (1) | EP0603650B1 (ja) |
| JP (1) | JP3875731B2 (ja) |
| AT (1) | ATE151071T1 (ja) |
| AU (1) | AU664930B2 (ja) |
| CA (1) | CA2111512C (ja) |
| DE (1) | DE59306029D1 (ja) |
| DK (1) | DK0603650T3 (ja) |
| ES (1) | ES2100435T3 (ja) |
| FI (1) | FI113860B (ja) |
| GR (1) | GR3023634T3 (ja) |
| HU (1) | HU215438B (ja) |
| IL (1) | IL108027A (ja) |
| NO (1) | NO300416B1 (ja) |
| NZ (1) | NZ250450A (ja) |
| TW (1) | TW384281B (ja) |
| ZA (1) | ZA939360B (ja) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ284456B6 (cs) * | 1992-02-15 | 1998-12-16 | Hoechst Aktiengesellschaft | Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje |
| ATE157351T1 (de) * | 1993-02-20 | 1997-09-15 | Hoechst Ag | Substituierte benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament, als inhibitoren des zellulären na+/h+-austauschs oder als diagnostikum sowie sie enthaltendes medikament |
| IL109570A0 (en) * | 1993-05-17 | 1994-08-26 | Fujisawa Pharmaceutical Co | Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof |
| DE4325822A1 (de) * | 1993-07-31 | 1995-02-02 | Hoechst Ag | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE4328869A1 (de) * | 1993-08-27 | 1995-03-02 | Hoechst Ag | Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE4337611A1 (de) * | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| DE4412334A1 (de) * | 1994-04-11 | 1995-10-19 | Hoechst Ag | Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE4422685A1 (de) * | 1994-06-29 | 1996-01-04 | Hoechst Ag | Ortho-amino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| IL114670A0 (en) * | 1994-08-05 | 1995-11-27 | Fujisawa Pharmaceutical Co | Guanidine derivatives pharmaceutical compositions containing the same and processes for the preparation thereof |
| DE4430213A1 (de) * | 1994-08-28 | 1996-02-29 | Merck Patent Gmbh | Arylbenzoylguanidine |
| DE4430916A1 (de) * | 1994-08-31 | 1996-03-07 | Merck Patent Gmbh | Alkyl-benzoylguanidin-Derivate |
| EP0765867A1 (de) * | 1995-09-27 | 1997-04-02 | Hoechst Aktiengesellschaft | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Antiarrhytmika oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19540995A1 (de) * | 1995-11-03 | 1997-05-07 | Hoechst Ag | Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19542306A1 (de) * | 1995-11-14 | 1997-05-15 | Hoechst Ag | Sulfonylamino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| PL316439A1 (en) * | 1995-11-20 | 1997-05-26 | Hoechst Ag | Novel substituted derivatives of benzoyloguanidine, method of obtaining them, their application in production of pharmaceutic and diagnostic agents and pharmaceutic agent as such |
| DE19546736A1 (de) * | 1995-12-14 | 1997-06-19 | Hoechst Ag | Substituierte Chromanylsulfonyl(thio)harnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Präparate |
| AU2003297629A1 (en) * | 2002-12-04 | 2004-06-23 | Ore Pharmaceuticals Inc. | Modulators of melanocortin receptor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3780027A (en) * | 1970-04-29 | 1973-12-18 | Merck & Co Inc | Anthranilic acid derivatives |
| DE3929582A1 (de) * | 1989-09-06 | 1991-03-07 | Hoechst Ag | Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament |
| GB9016579D0 (en) * | 1990-07-27 | 1990-09-12 | Ici Plc | Fungicides |
-
1993
- 1993-12-08 DK DK93119784.2T patent/DK0603650T3/da active
- 1993-12-08 ES ES93119784T patent/ES2100435T3/es not_active Expired - Lifetime
- 1993-12-08 EP EP93119784A patent/EP0603650B1/de not_active Expired - Lifetime
- 1993-12-08 AT AT93119784T patent/ATE151071T1/de active
- 1993-12-08 DE DE59306029T patent/DE59306029D1/de not_active Expired - Lifetime
- 1993-12-14 AU AU52405/93A patent/AU664930B2/en not_active Ceased
- 1993-12-14 NZ NZ250450A patent/NZ250450A/en not_active IP Right Cessation
- 1993-12-14 ZA ZA939360A patent/ZA939360B/xx unknown
- 1993-12-14 FI FI935617A patent/FI113860B/fi not_active IP Right Cessation
- 1993-12-15 CA CA002111512A patent/CA2111512C/en not_active Expired - Fee Related
- 1993-12-15 NO NO934634A patent/NO300416B1/no not_active IP Right Cessation
- 1993-12-15 HU HU9303596A patent/HU215438B/hu not_active IP Right Cessation
- 1993-12-15 JP JP31459293A patent/JP3875731B2/ja not_active Expired - Fee Related
- 1993-12-15 IL IL10802793A patent/IL108027A/en not_active IP Right Cessation
- 1993-12-17 TW TW082110702A patent/TW384281B/zh active
-
1995
- 1995-05-25 US US08/450,225 patent/US5516805A/en not_active Expired - Lifetime
-
1997
- 1997-05-30 GR GR970401280T patent/GR3023634T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO934634L (no) | 1994-06-17 |
| AU5240593A (en) | 1994-06-30 |
| CA2111512C (en) | 2005-11-15 |
| FI935617A (fi) | 1994-06-17 |
| GR3023634T3 (en) | 1997-08-29 |
| EP0603650A1 (de) | 1994-06-29 |
| IL108027A0 (en) | 1994-04-12 |
| DE59306029D1 (de) | 1997-05-07 |
| ZA939360B (en) | 1994-08-08 |
| ATE151071T1 (de) | 1997-04-15 |
| NZ250450A (en) | 1995-08-28 |
| CA2111512A1 (en) | 1994-06-17 |
| IL108027A (en) | 1998-12-06 |
| FI935617A0 (fi) | 1993-12-14 |
| DK0603650T3 (da) | 1997-10-20 |
| TW384281B (en) | 2000-03-11 |
| HUT65747A (en) | 1994-07-28 |
| EP0603650B1 (de) | 1997-04-02 |
| AU664930B2 (en) | 1995-12-07 |
| NO934634D0 (no) | 1993-12-15 |
| HU9303596D0 (en) | 1994-04-28 |
| FI113860B (fi) | 2004-06-30 |
| US5516805A (en) | 1996-05-14 |
| JP3875731B2 (ja) | 2007-01-31 |
| ES2100435T3 (es) | 1997-06-16 |
| HU215438B (hu) | 2000-12-28 |
| JPH06256290A (ja) | 1994-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU658262B2 (en) | Ortho-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic and medicaments containing them | |
| AU668265B2 (en) | Substituted benzoylguanidines, process for their preparation, their use as a pharmaceutical, as inhibitors of the cellular N+/H+ exchange or as a diagnostic, and pharmaceutical containing them | |
| EP0686627B1 (de) | Perfluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament | |
| AU658261B2 (en) | Amino-substituted benzoylguanidines, process for their preparation, their use as a medicament and medicament containing them | |
| NO179946B (no) | Benzoylguanidiner og deres anvendelse som medikamenter | |
| EP0640588B1 (de) | Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament | |
| NO179549B (no) | 3,5-substituerte benzoylguanidiner og deres anvendelse som medikament eller diagnostikum | |
| EP0659748B1 (de) | Substituierte 1,1-dioxo-2H-1,2-benzothiazinoylguanidine mit Na+/H+-Austausch inhibierender Wirkung | |
| NO300416B1 (no) | 3,5-substituerte aminobenzoylguanidiner, deres anvendelse til fremstilling av medikament eller diagnostikum | |
| NO179673B (no) | 3,4,5-substituerte benzoylguanidiner og anvendelse av forbindelsene for fremstilling av legemidler | |
| EP0604852A1 (de) | 2,4-Substituierte 5-(N-substituierte-Sulfamoyl)-Benzoylguanidine, als Antiarrythmika, Inhibitoren der Proliferationen von Zellen, und Inhibitoren des Natrium-Protonen-Antiporters | |
| NO300679B1 (no) | Substituerte benzoylguanidiner, deres anvendelse for fremstilling av medikament eller diagnostikum samt medikament inneholdende forbindelsen | |
| NO300680B1 (no) | Ureasubstituerte benzoylguanidiner, deres anvendelse for fremstilling av medikament eller diagnostikum samt medikament inneholdende forbindelsene | |
| EP0765867A1 (de) | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Antiarrhytmika oder Diagnostikum sowie sie enthaltendes Medikament | |
| JPH0812643A (ja) | ｏ−アミノ置換ベンゾイルグアニジンおよびその製造方法 | |
| RU2165412C2 (ru) | Бензоилгуанидины, способ их получения, способ ингибирования, фармацевтический состав и способ его получения | |
| EP0702001B1 (de) | Trifluoropropyl-substituierte Benzoylguanidine und ihre Verwendung als Medikament oder Diagnostikum | |
| DE4441880A1 (de) | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament | |
| NO315424B1 (no) | Substituerte tiofenalkenylkarboksylsyreguanidider, fremgangsmåter for deresfremstilling, deres anvendelse for fremstilling av medikamenteller diagnostikum samt medikament inneholdende forbindelsene | |
| EP1259481A1 (de) | Substituierte benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum sowie sie enthaltendes medikament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |